October 29, 2026

Ethical Concerns Surround Alicia Jackson’s Role in HHS

In November, the Department of Health and Human Services (HHS) decided to remove “black box” warnings from hormone replacement therapies. Alicia Jackson, director of a health agency, supported this move for menopause treatment. She claimed it could extend healthy years for women, saying the therapy is safe and effective.

Jackson’s financial ties raise questions. She founded Evernow, a menopause treatment platform, and retained at least $115,000 in its stock. This potential conflict of interest comes as she leads the Advanced Research Projects Agency for Health (ARPA-H).

Her involvement in the warning removal remains uncertain. The FDA, not ARPA-H, regulates such decisions. Months before her government role, experts recommended ending the warning. Yet, Jackson’s endorsement has been criticized as a conflict of interest by ethics experts.

“Her company could profit from the changes she endorsed,” ethics lawyer Virginia Canter stated.

Jackson’s financial disclosures are uncertified, adding complexity to her case. ProPublica highlighted these issues and reported her administrative leave from HHS.

A leaked memo suggests a conflict waiver might have allowed Jackson to participate in certain decisions affecting personal investments. Evernow was not part of this waiver.

Jackson has substantial investments through venture capital and private equity funds. Notably, her husband co-founded 137 Ventures, a firm investing in various sectors. The lack of disclosure about these funds poses ethical concerns.

The potential conflict extends to Palantir Technologies, where Jackson’s husband holds significant stock. Jackson’s role at ARPA-H included overseeing contracts with Palantir, intensifying ethics scrutiny.

Efforts to address these issues continue. ProPublica’s investigations shed light on ethical challenges within the Trump administration. The disclosures reveal conflicts across government levels, impacting transparency and accountability.

TAGS: